LNC Technology Co., Ltd. (4587)

Overview

PeptiDream Inc. is a biopharmaceutical company founded in 2006 and headquartered in Kawasaki, Japan. The company specializes in the discovery and development of therapeutics based on constrained peptides, small molecules, and peptide-drug conjugates. Utilizing its innovative Peptide Discovery Platform System (PDPS), PeptiDream Inc. is able to produce unique non-standard peptide libraries. This revolutionary platform facilitates the identification of macrocyclic peptide candidates that exhibit both potent and selective activities. These candidates are then developed into a range of therapeutics and diagnostics, including peptide-based, small molecule-based, and multi-functional peptide conjugates. Furthermore, through its subsidiary, PDRadiopharma Inc., PeptiDream expands its footprint in the biopharmaceutical sector by engaging in the research, development, manufacture, and sale of various radiopharmaceuticals and radiodiagnostic products.

Products and Services

• PD-L1 for Oncology

  Currently in Phase 1 clinical development, this therapeutic candidate is designed to target PD-L1, a critical protein involved in suppressing the immune response against cancer cells.

• PD-L1 BMS-986229 for Oncology

  Also in Phase 1 clinical development, this variant of PD-L1 therapy is tailored for enhanced effectiveness in oncology applications.

• CD38 BHV-1100 + NK Cells for Multiple Myeloma

  A Phase 1 clinical stage candidate that combines BHV-1100 with NK cells to target CD38, a molecule highly expressed in multiple myeloma cells.

• S2-protein PA-001 for COVID-19

  Addressing the urgent need for COVID-19 therapeutics, this Phase 1 candidate targets the S2 protein of the coronavirus, aimed at neutralizing the virus.

• GhR AZP-3813 for Acromegaly/NET

  In Phase 1 development, this candidate targets the Growth Hormone Receptor (GhR) for potential treatment of acromegaly and neuroendocrine tumors (NET).

• Glypican-3 for Liver Cancer

  Currently in the preclinical stage, this product aims at targeting Glypican-3, a protein implicated in the progression of liver cancer.

• Myostatin for DMD/Muscle Disorders

  This preclinical stage candidate is being developed to target myostatin for potential treatment of Duchenne Muscular Dystrophy (DMD) and other muscle disorders.

• TfR for Neuromuscular Disorders

  Targeting the Transferrin Receptor (TfR), this candidate is in the preclinical stage for the treatment of various neuromuscular disorders.

• c-Kit for Allergic Conditions

  Under preclinical development, this therapy targets c-Kit, a receptor tyrosine kinase involved in the regulation of cell processes, for treating allergic conditions.

• c-Met

  Also in the preclinical development stage, this candidate focuses on targeting c-Met, a receptor tyrosine kinase that has been implicated in various forms of cancer.

• HA-protein for Influenza

  This preclinical candidate targets the HA protein of the influenza virus, offering a potential new avenue for influenza treatment.